11-47352645-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1PS1_ModeratePM2
The NM_000256.3(MYBPC3):c.3G>A(p.Met1?) variant causes a start lost change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000188 in 1,595,446 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.0000066 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000014 ( 0 hom. )
Consequence
MYBPC3
NM_000256.3 start_lost
NM_000256.3 start_lost
Scores
6
6
4
Clinical Significance
Conservation
PhyloP100: 1.83
Genes affected
MYBPC3 (HGNC:7551): (myosin binding protein C3) MYBPC3 encodes the cardiac isoform of myosin-binding protein C. Myosin-binding protein C is a myosin-associated protein found in the cross-bridge-bearing zone (C region) of A bands in striated muscle. MYBPC3 is expressed exclusively in heart muscle and is a key regulator of cardiac contraction. Mutations in this gene are a frequent cause of familial hypertrophic cardiomyopathy. [provided by RefSeq, May 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Start lost variant, no new inframe start found.
PS1
Another start lost variant in NM_000256.3 (MYBPC3) was described as [Conflicting_classifications_of_pathogenicity] in ClinVar as 42747
PM2
Very rare variant in population databases, with high coverage;
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MYBPC3 | NM_000256.3 | c.3G>A | p.Met1? | start_lost | 1/35 | ENST00000545968.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.3G>A | p.Met1? | start_lost | 1/35 | 5 | NM_000256.3 | P4 | |
MYBPC3 | ENST00000399249.6 | c.3G>A | p.Met1? | start_lost | 1/34 | 5 | A2 | ||
MYBPC3 | ENST00000544791.1 | c.3G>A | p.Met1? | start_lost, NMD_transcript_variant | 1/27 | 5 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152112Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
1
AN:
152112
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000433 AC: 1AN: 231038Hom.: 0 AF XY: 0.00000793 AC XY: 1AN XY: 126104
GnomAD3 exomes
AF:
AC:
1
AN:
231038
Hom.:
AF XY:
AC XY:
1
AN XY:
126104
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000139 AC: 2AN: 1443334Hom.: 0 Cov.: 30 AF XY: 0.00 AC XY: 0AN XY: 717890
GnomAD4 exome
AF:
AC:
2
AN:
1443334
Hom.:
Cov.:
30
AF XY:
AC XY:
0
AN XY:
717890
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152112Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74316
GnomAD4 genome
AF:
AC:
1
AN:
152112
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74316
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
1
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:3
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Hypertrophic cardiomyopathy Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Jun 15, 2023 | This variant results in the loss of the translation initiator methionine at codon 1 of the MYBPC3 protein. This variant is expected to disrupt the expression of the full-length MYBPC3 protein. The next in-frame methionine occurs at codon 103 in the Ig-like domain C0. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in compound heterozygous state with a truncation variant (p. Ile292PhefsTer8) in two siblings affected with hypertrophic cardiomyopathy, and in heterozygous state in their unaffected mother (PMID: 29524613). Different single nucleotide substitutions (c.3G>C, c.1A>T) causing the same initiator codon loss have been reported in two probands affected with hypertrophic cardiomyopathy (PMID: 25611685, 27532257). This variant has been identified in 2/262394 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 27, 2021 | This sequence change affects the initiator methionine of the MYBPC3 mRNA. The next in-frame methionine is located at codon 103. This variant is present in population databases (rs397516045, ExAC 0.01%). Disruption of the initiator codon has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 25611685, 27532257, 29524613). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 02, 2023 | Observed with a frameshift variant on the opposite allele (in trans) in twin siblings with hypertrophic cardiomyopathy in published literature; the c.3G>A variant was heterozygous in the asymptomatic father with normal echocardiogram (Zhou et al., 2018); Observed in a cohort of patients with sporadic dilated cardiomyopathy, although patient specific clinical information and familial segregation information were not provided (Xiao et al., 2021); Initiation codon variant in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 28679633, 29524613, 33996946) - |
Cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Jun 06, 2023 | This variant results in the loss of the translation initiator methionine at codon 1 of the MYBPC3 protein. This variant is expected to disrupt the expression of the full-length MYBPC3 protein. The next in-frame methionine occurs at codon 103 in the Ig-like domain C0. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in compound heterozygous state with a truncation variant (p. Ile292PhefsTer8) in two siblings affected with hypertrophic cardiomyopathy, and in heterozygous state in their unaffected parent (PMID: 29524613). It has also been reported in an individual affected with dilated cardiomyopathy (PMID: 33996946). Different single nucleotide substitutions (c.3G>C, c.1A>T) causing the same initiator codon loss have been reported in individuals affected with hypertrophic cardiomyopathy (PMID: 25611685, 27532257, 30297972; communication with an external laboratory; ClinVar SCV003852942.1, SCV001504154.3). This variant has been identified in 2/262394 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;T;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D
MetaSVM
Benign
T
MutationTaster
Benign
D;D;D
PROVEAN
Benign
N;N;N
REVEL
Uncertain
Sift
Pathogenic
D;D;D
Sift4G
Pathogenic
D;D;D
Polyphen
P;.;.
Vest4
MutPred
Gain of catalytic residue at M1 (P = 0.0885);Gain of catalytic residue at M1 (P = 0.0885);Gain of catalytic residue at M1 (P = 0.0885);
MVP
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at